Project Grant F30CA291094
Award Date
9/30/24
Completion Date
4/28/28
Dollars Obligated
$342K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48202, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the role of microbes in pancreatic cancer development and metastasis. The $537,985 award, covering the period from August 1, 2024 to July 31, 2029, will support in-depth characterization of the location, distribution, and spatial functionality of microbes within the pancreatic tumor...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to characterize the role of mesothelial-derived cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDA). The $139,445 award to the Regents of the University of Michigan will fund a 4-year research project to: 1) determine the contribution of WT1+ mesothelial cells to the fibroblast compartment in PDA, and 2) evaluate the functional role...
The U.S. National Cancer Institute (NCI) awarded a $110,550 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, which runs from September 10, 2025 to May 31, 2026, supports research focused on understanding the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. The research aims to investigate how the lymph...
The University of Miami has been awarded a 5-year, $351,131 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research aimed at overcoming chemoimmunotherapy resistance in pancreatic cancer. The key focus of the project is to mechanistically dissect the signaling interactions between immunosuppressive myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to therapeutic resistance, as well as develop a...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $103,948 to Wayne State University to investigate the role of the Ran guanine exchange factor, RCC1, in pancreatic ductal adenocarcinoma (PDAC) progression. The research aims to understand how RCC1 alters PDAC metabolic activity and mRNA processing to drive tumor progression, as well as examine the RAN-RCC1 axis in metastatic PDAC using...
The National Cancer Institute (NCI) awarded a $453,304 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the University of Texas MD Anderson Cancer Center. The grant, which runs from September 1, 2024 to August 31, 2029, will fund research to investigate how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The researchers will use genetically engineered mouse models and...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a performance period from March 1, 2025 to February 28, 2027, will support research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven hepatocellular carcinoma. The project aims to determine how TSC1-deficient hepatic macrophages can...
This $138,742 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a research project at The Johns Hopkins University to investigate how combination immunotherapy alters cellular communication networks in pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: 1) develop statistical methods to identify differential cellular interactions between immunotherapy treatment groups using single-cell RNA sequencing data from PDAC clinical...
This Project Grant award, funded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports research to determine the role of microRNA-29a (miR-29a) in regulating T-cell dysfunction in pancreatic ductal adenocarcinoma (PDAC). The $107,948 award, effective December 17, 2024 through July 31, 2028, aims to: 1) Alter the differentiation of terminally exhausted CD8 T-cells to a more progenitor and memory-like phenotype, and validate this combination strategy...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The research focuses on two key lysosomal hydrolases, PLBD1 and LGMN, which are found to be essential for pancreatic ductal adenocarcinoma (PDAC) growth. The project will explore PLBD1's...